MarketPulse

solid tumors

12 articles
BenzingaBenzinga··Prnewswire

NWBO Bolsters Leadership With Veteran Pharma Executive to Expand Cancer Vaccine Platform

Northwest Biotherapeutics appoints experienced biopharma executive Dr. Annalisa Jenkins as Strategic Adviser to advance its DCVax dendritic cell cancer vaccine platform.
NWBOpersonalized medicinesolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Euda Health Holdings Limited

EUDA Partner Secures Shenzhen R&D Funding for TCR-T Cell Therapy Development

EUDA's partner Shenzhen Inno Immune wins Chinese government R&D funding approval for TCR-T cell therapy development targeting solid tumors.
EUDAEUDAWcancer treatmentsolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aktis Oncology Advances Radioconjugate Pipeline With First AKY-2519 Clinical Data

Aktis Oncology presents inaugural clinical data for AKY-2519 radioconjugate at ASCO 2026, with Phase 1b trial launching mid-year following FDA IND clearance.
AKTSsolid tumorsFDA clearance
GlobeNewswire Inc.GlobeNewswire Inc.··Beyond Air, Inc.

Beyond Cancer's UNO Therapy Shows Durable Survival Gains in Early-Stage Cancer Trial

Beyond Cancer presented Phase 1 UNO trial data with six of ten patients alive 22-40 months post-treatment and secured U.S. patent for gas delivery technology.
XAIRbreast cancercancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mestag's MST-0312 Advances to AACR Stage Ahead of Mid-2026 Clinical Launch

Mestag Therapeutics' FAP-targeted bispecific antibody MST-0312 selected for late-breaking AACR presentation in April 2026, with Phase 1 trials expected to begin mid-year.
JNJMRKsolid tumorsbispecific antibody
BenzingaBenzinga··Vandana Singh

Telix Pharma Surges on $2.14B Regeneron Deal for Solid Tumor Radiotherapies

Telix Pharma secures $2.14B partnership with Regeneron for solid tumor radiopharmaceuticals while reporting 11% quarterly revenue growth and FDA acceptance of brain cancer imaging application.
TLXREGNFDA approvalsolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Advances TCR Cell Therapy Pipeline With FDA Clearance, Conference Participation

TScan Therapeutics secures FDA clearance for two IND applications and completes Phase 1 trial enrollment using commercial-scale manufacturing, advancing its TCR cell therapy pipeline.
TCRXclinical-stage biotechsolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ipsen Unveils Early-Stage Immuno-Oncology Breakthroughs at AACR Congress

Ipsen presents preclinical data for two first-in-class cancer candidates targeting solid tumors and gastrointestinal cancers, advancing its immuno-oncology pipeline.
IPSEYantibody-drug conjugatesolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Launches Global Trial for Dual-Action Tumor Therapy HMPL-A580

HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a novel antibody-targeted therapy combining PI3K/PIKK inhibitor with anti-EGFR antibody for solid tumors across China and US.
HCMclinical developmentsolid tumors
BenzingaBenzinga··Globe Newswire

Bicara Therapeutics Raises $172.5M in Oversubscribed Offering

Bicara Therapeutics raises $172.5M in oversubscribed offering, with proceeds funding development of lead immunotherapy candidate ficerafusp alfa for solid tumors.
BCAXclinical-stageEGFR
BenzingaBenzinga··Globe Newswire

Bicara Therapeutics Plans $150M Stock Offering to Fund Pipeline Advancement

Bicara Therapeutics plans $150M stock offering to advance its lead drug candidate ficerafusp alfa through clinical development and build commercial infrastructure for potential market launch.
BCAXclinical-stageEGFR
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Calidi Biotherapeutics Advances Tumor-Targeted BiTE Platform Toward Clinical Development

Calidi Biotherapeutics advances RedTail virotherapy platform combining BiTE and IL-15 therapies for solid tumors, aiming to overcome immunosuppressive microenvironments. IND submission planned for 2026.
CLDIsolid tumorsRedTail platform